RESUMO

Hepatitis B (HBV) is a public health problem worldwide; one-third of the population has already been in contact with HBV, and 350 million people are chronic carriers of virus. The appearance of hyperimmune gamma globulin and antiviral drugs has allowed that group to undergone hepatic transplantation, achieving satisfactory results to prevent a relapse. But the use of hyperimmune gamma globulin has an extremely high cost, and combined therapies with new antiviral drugs seem to be a therapeutic alternative. We analyzed 21 patients with hepatitis B associated or not with Delta hepatitis over a mean follow-up period of 19.5 months, concluding that use of only nucleotide analogues has sufficient to achieve satisfactory results.

Assuntos

Antivirais/uso terapêutico , Hepatite B/cirurgia , Hepatite D/cirurgia , Transplante de Fígado/imunologia , Adenina/análogos & derivados , Adenina/uso terapêutico , Adulto , Idoso , Aspartato Aminotransferases/sangue , Feminino , Guanina/análogos & derivados , Guanina/uso terapêutico , Hepatite B/complicações , Hepatite B/tratamento farmacológico , Hepatite B/prevenção & controle , Vírus da Hepatite B/efeitos dos fármacos , Vírus da Hepatite B/genética , Hepatite D/complicações , Hepatite D/tratamento farmacológico , Humanos , Masculino , Pessoa de Meia-Idade , Organofosfonatos/uso terapêutico , Reação em Cadeia da Polimerase , Recidiva , Estudos Retrospectivos , Adulto Jovem